The Oncofetal Protein IMP3: A Novel Grading Tool and Predictor of Poor Clinical Outcome in Human Gliomas

Figure 2

Cox proportional-hazards regression analyses of IMP3-positive and IMP3-negative HGGs for overall ((a), (c), and (e)) or disease-free survival ((b), (d), and (f)). IMP3 presence is a poor prognostic factor either considering high-grade gliomas (, HR: 0.3392, 95% CI: 0.1928–0.5965 and , HR: 0.4586, 95% CI: 0.2631 to 0.7994 for OS and DFS, resp.) or separately grade III (, HR: 4.47, 95% CI: 1.19–16.8 and , HR: 13.30, 95% CI: 1.44–122.6 for OS and DFS, resp.) and GBM (, HR: 0.41, 95% CI: 0.19 to 0.84 and , HR: 0.5, 95% CI: 0.23–0.98 for OS and DFS, resp.) patients.

(a)

(b)

(c)

(d)

(e)

(f)